Congenital disorders of glycosylation (CDG): Quo vadis ? - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Medical Genetics Année : 2018

Congenital disorders of glycosylation (CDG): Quo vadis ?


The survey summarizes in its first part the current status of knowledge on the Congenital Disorders of Glycosylation (CDG) with regard to their phenotypic spectrum, diagnostic and therapeutic strategies, and pathophysiology. It documents the clinical and basic research activities, and efforts to involve patients and their families. In the second part, it tries to look into the future of CDG. More specific biomarkers are needed for fast CDG diagnosis and treatment monitoring. Whole genome sequencing will play an increasingly important role in the molecular diagnosis of unsolved CDG. Epigenetic defects are expected to join the rapidly expanding genetic and allelic heterogeneity of the CDG family. Novel treatments are urgently needed particularly for PMM2-CDG, the most prevalent CDG. Patient services such as apps should be developed e.g. to document the natural history and monitor treatment. Networking (EURO-CDG, the European Reference Networks (MetabERN)) is an efficient tool to disseminate knowledge and boost collaboration at all levels. The final goal is of course to improve the quality of life of the patients and their families.
Fichier principal
Vignette du fichier
1-s2.0-S1769721217304949-main.pdf (13.24 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03181211 , version 1 (25-03-2021)





Romain Péanne, Pascale de Lonlay, Francois Foulquier, Uwe Kornak, Dirk J. Lefeber, et al.. Congenital disorders of glycosylation (CDG): Quo vadis ?. European Journal of Medical Genetics, 2018, 61 (11), pp.643-663. ⟨10.1016/j.ejmg.2017.10.012⟩. ⟨hal-03181211⟩
32 Consultations
54 Téléchargements



Gmail Facebook X LinkedIn More